US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pacer WealthShield ETF

31.30

0.0000

Volume:18.00

Turnover:561.63

Market Cap:26.61M

PE:- -

High:31.30

Open:31.30

Low:31.30

Close:31.30

Loading ...

Overview Company News Filings

Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET

Soleno Therapeutics seeking regulatory approval in treatment of PWS

Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET

Soleno Therapeutics Announces VYKAT(TM) XR Launch

Press Release: Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug

Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Soleno Therapeutics to Participate in Upcoming February Investor Conferences

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PWS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PWS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PWS\",,,,,undefined,":{"symbol":"PWS","market":"US","secType":"STK","nameCN":"Pacer WealthShield ETF","latestPrice":31.3004,"timestamp":1753732800000,"preClose":31.3004,"halted":0,"volume":18,"delay":0,"floatShares":850000,"shares":850000,"eps":0,"marketStatus":"Post-Mkt","change":0,"latestTime":"07-28 16:23:13 EDT","open":31.3004,"high":31.3004,"low":31.3004,"amount":561.6335,"amplitude":0,"askPrice":46.78,"askSize":200,"bidPrice":15.6,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1753747200000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"BATS","adjPreClose":31.3004,"sharesOutstanding":850000,"nav":31.11,"aum":26443500,"dividendRate":0.015974,"bidAskSpread":0.001693,"volumeRatio":0.038071},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PWS\",,,,,undefined,":{"symbol":"PWS","floatShares":850000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.038071,"shares":850000,"dividePrice":0.5,"high":31.3004,"amplitude":0,"preClose":31.3004,"low":31.3004,"week52Low":28.63,"pbRate":"--","week52High":32.64,"institutionHeld":0,"latestPrice":31.3004,"eps":0,"divideRate":0.015974,"volume":18,"delay":0,"ttmEps":0,"open":31.3004,"prevYearClose":30.4061,"prevWeekClose":31.3004,"prevMonthClose":30.3302,"prevQuarterClose":30.3302,"fiveDayClose":30.8844,"twentyDayClose":30.2478,"sixtyDayClose":30.78},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PWS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2554779787","title":"Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET","url":"https://stock-news.laohu8.com/highlight/detail?id=2554779787","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554779787?lang=en_us&edition=fundamental","pubTime":"2025-07-28 20:00","pubTimestamp":1753704000,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., July  28, 2025  (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare disea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/28/3122407/0/en/Soleno-Therapeutics-to-Report-Second-Quarter-2025-Financial-Results-on-August-6-2025-at-4-30-PM-ET.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4561","ET","BK4585","BK4144","SLNO","BK4588","BK4139","BK4581","BK4590","PWS"],"gpt_icon":0},{"id":"2537204529","title":"Soleno Therapeutics seeking regulatory approval in treatment of PWS","url":"https://stock-news.laohu8.com/highlight/detail?id=2537204529","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537204529?lang=en_us&edition=fundamental","pubTime":"2025-05-23 05:40","pubTimestamp":1747950020,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics (SLNO) “announced that Soleno’s Marketing Authorization Application seeking regulatory approval of Diazoxide Choline Prolonged-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/soleno-therapeutics-seeking-regulatory-approval-in-treatment-of-pws-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/soleno-therapeutics-seeking-regulatory-approval-in-treatment-of-pws-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SLNO","PWS"],"gpt_icon":0},{"id":"2529750792","title":"Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET","url":"https://stock-news.laohu8.com/highlight/detail?id=2529750792","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529750792?lang=en_us&edition=fundamental","pubTime":"2025-04-23 19:00","pubTimestamp":1745406000,"startTime":"0","endTime":"0","summary":"The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website, www.soleno.life.INDICATIONVYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome .Risk of Fluid OverloadEdema, including severe reactions associated with fluid overload, has been reported. Monitor for signs or symptoms of edema or fluid overload. VYKAT XR has not been studied in patients with compromised cardiac reserve and should be used with caution in these patients.Adverse ReactionsThe most common adverse reactions  included hypertrichosis, edema, hyperglycemia, and rash.Please see the fullPrescribing Information, including Medication Guide.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/soleno-therapeutics-report-first-quarter-110000138.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4590","BK4144","BK4139","BK4561","BK4588","BK4581","ET","PWS","SLNO","BK4181","BK4218","HST"],"gpt_icon":0},{"id":"2527538461","title":"Soleno Therapeutics Announces VYKAT(TM) XR Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2527538461","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527538461?lang=en_us&edition=fundamental","pubTime":"2025-04-14 19:00","pubTimestamp":1744628400,"startTime":"0","endTime":"0","summary":"First prescriptions delivered to individuals with PWSREDWOOD CITY, Calif., April  14, 2025  (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developin","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/14/3060770/0/en/Soleno-Therapeutics-Announces-VYKAT-TM-XR-Launch.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TM","PWS","BK4555","BK4588","SLNO","BK4585","03160","BK4604","BK4099","BK4139"],"gpt_icon":0},{"id":"2524097441","title":"Press Release: Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2524097441","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524097441?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:10","pubTimestamp":1743451800,"startTime":"0","endTime":"0","summary":"-- Lead candidate ARD-101 demonstrated clinical activity and was generally. well tolerated in a two-part Phase 2 trial in Prader-Willi Syndrome ,with meaningful reductions in hyperphagia (up to a 16-point HQ-CT. reduction, with an average reduction of approximately 8 points among. subjects that followed trial protocol) observed during the 28-day dosing. -- DEXA scans analysis from the PWS Phase 2 trial data measuring body. composition indicated a trend toward decreased body fat (approximately. -- Aardvark bolstered its cash runway through the successful completion of. SAN DIEGO, March 31, 2025  -- Aardvark Therapeutics, Inc.  , a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the full year ended December 31, 2024, and provided business highlights.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPO","AARD","PWS"],"gpt_icon":0},{"id":"2522653140","title":"Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522653140","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522653140?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:05","pubTimestamp":1743105900,"startTime":"0","endTime":"0","summary":"Expect Topline Phase 2 data for NDV-01 for high-grade non-muscle invasive bladder cancer, to be presented at AUA 2025 in April. Advancing novel neurosteroid, sepranolone, towards Phase 2b study in Tourette syndrome with plans for evaluation in other compulsion-related disorders, including Prader-Willi Syndrome. Cash balance of $44.8 million as of December 31 2024. Management hosting conference call and webcast today at 4:30 PM ET. “An important dimension of our strategic options exploration has been the development of a portfolio of programs with near-term value drivers that can address under-served markets. While we maintain deep expertise in diseases of the central nervous system, as we evaluate strategic opportunities, the broad drug development expertise of our Team provides flexibility to be opportunistic,” commented Maged Shenouda, CFO of Relmada. “With a $44.8 million cash balance, as of December 31, 2024, and clean balance sheet, we begin the year with solid financial strength.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/relmada-therapeutics-reports-fourth-quarter-200500181.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4179","BK4139","CDC","PAM","TS","PWS","RLMD","ALLO","BK4007","LENZ","BK4532","BK4505","IE00B1B80R65.USD","BK4563","BK4081"],"gpt_icon":0},{"id":"2522003463","title":"SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2522003463","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522003463?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:46","pubTimestamp":1743079560,"startTime":"0","endTime":"0","summary":"Shares of Soleno TherapeuticsSLNO have rallied 37% in the premarket hours today following the FDA approval of Vykat XR extended-release tablets for treating hyperphagia in adults and children aged four years and older with Prader-Willi syndrome . The company expects to launch the drug in the United States in April 2025.Soleno’s Vykat XR, previously referred to as DCCR, is an innovative, once-daily, proprietary extended-release dosage form that contains diazoxide choline, the crystalline salt form of diazoxide. Although not approved for treating PWS, the parent molecule, diazoxide, treats a few rare diseases in neonates, infants, children and adults.Per the PWS Association USA, approximately one in every 15,000 newborns suffers from this rare genetic disorder. The most common symptom of PWS is hyperphagia, an abnormally increased appetite for food, often leading to excessive eating, which takes a serious toll on the quality of life of patients suffering from it. In the long term, hyperp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/slno-stock-rallies-fda-approval-124600150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065171402.SGD","PWS","BAYRY","CORT","ACAD","LU1559883803.SGD","BK4139","BK4532","LU2065170008.USD","LU2065171311.SGD","SLNO","LU0566484027.USD","LU2065169927.USD","BK4007"],"gpt_icon":0},{"id":"2522935620","title":"Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2522935620","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522935620?lang=en_us&edition=fundamental","pubTime":"2025-03-27 05:15","pubTimestamp":1743023700,"startTime":"0","endTime":"0","summary":"First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome. Management to host conference call and webcast today, March 26th, at 5:30pm ET. REDWOOD CITY, Calif., March 26, 2025  -- Soleno Therapeutics, Inc. , a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration  has approved VYKAT XR  extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome . Soleno expects VYKAT XR to be available in the U.S. beginning in April 2025.The FDA approval of VYKAT XR was based on an adequate and well-controlled study and safety data from the comprehensive clinical development program. Efficacy was established during the 16-week r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/soleno-therapeutics-announces-u-fda-211500828.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PWS","SLNO"],"gpt_icon":0},{"id":"2514839106","title":"Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514839106","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514839106?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:00","pubTimestamp":1740571200,"startTime":"0","endTime":"0","summary":"-- Fourth quarter 2024 net revenue from global sales of IMCIVREE  of $41.8 million --. -- On track to report topline data from global Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity in the second quarter of 2025 --. -- Completed enrollment in the Phase 2 trial of oral MC4R agonist bivamelagon in acquired hypothalamic obesity --. -- FDA approved expanded label for IMCIVREE to include children as young as 2 years old --. -- Raised approximately $75 million in gross proceeds under ATM equity offering program; Cash runway extended into 2027 --. BOSTON, Feb. 26, 2025  -- Rhythm Pharmaceuticals, Inc. , a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2024.Today, Rhythm announced a strategic partnership agreement with Trispera Pharma Solutions in Turkey;","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rhythm-pharmaceuticals-reports-fourth-quarter-120000027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4139","EC","PWS","BK4585","RYTM","BK4201"],"gpt_icon":0},{"id":"2507630836","title":"Soleno Therapeutics to Participate in Upcoming February Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2507630836","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507630836?lang=en_us&edition=fundamental","pubTime":"2025-01-30 05:05","pubTimestamp":1738184700,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., Jan.  29, 2025  (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatmen","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/29/3017568/0/en/Soleno-Therapeutics-to-Participate-in-Upcoming-February-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PWS","SLNO","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PWS\",params:#limit:5,,,undefined,":[{"date":"2025-06-05","symbol":"PWS","amount":0.116206,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-05","defaultRemindTime":1749130200000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-11","payableDate":"2025-06-05","currency":"USD","dateTimestamp":1749096000000,"payDate":"2025-06-11"},{"date":"2025-03-06","symbol":"PWS","amount":0.059681,"announcedDate":"2025-03-05","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-06","defaultRemindTime":1741271400000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-12","payableDate":"2025-03-06","currency":"USD","dateTimestamp":1741237200000,"payDate":"2025-03-12"},{"date":"2024-12-27","symbol":"PWS","amount":0.206094,"announcedDate":"2024-12-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-27","defaultRemindTime":1735309800000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-01-02","payableDate":"2024-12-27","currency":"USD","dateTimestamp":1735275600000,"payDate":"2025-01-02"},{"date":"2024-09-26","symbol":"PWS","amount":0.121716,"announcedDate":"2024-09-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-09-26","defaultRemindTime":1727357400000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-10-02","payableDate":"2024-09-26","currency":"USD","dateTimestamp":1727323200000,"payDate":"2024-10-02"},{"date":"2024-06-27","symbol":"PWS","amount":0.047202,"announcedDate":"2024-06-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-27","defaultRemindTime":1719495000000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-03","payableDate":"2024-06-27","currency":"USD","dateTimestamp":1719460800000,"payDate":"2024-07-03"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PWS\",market:\"US\",,,undefined,":[{"executeDate":"2018-03-27","recordDate":"2018-03-28","paymentDate":"2018-03-29","value":0.0522982,"currency":"USD"},{"executeDate":"2018-06-26","recordDate":"2018-06-27","paymentDate":"2018-06-28","value":0.0481106,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-09-27","value":0.1105742,"currency":"USD"},{"executeDate":"2018-12-24","recordDate":"2018-12-26","paymentDate":"2018-12-27","value":0.0682115,"currency":"USD"},{"executeDate":"2019-03-26","recordDate":"2019-03-27","paymentDate":"2019-03-28","value":0.1385698,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PWS\",market:\"US\",delay:false,,,undefined,":{}}}